Thursday, December 10, 2020

Janssen selected Feel Therapeutics for new accelerator focused on predictive diagnostics and precision treatment

3 min read
Written by

Feel Therapeutics

San Francisco, CA, December 10,2020 — Feel Therapeutics, Inc., was recently selected as an awardee of the prestigious Janssen Digital Solutions QuickFire Challenge to submit solutions with the potential to scale for impact across EMEA within the next five years. Janssen, the pharmaceutical company of Johnson & Johnson, is driven by a desire to prevent disease and will help Feel Therapeutics with resources needed to maximize the potential of developing new, outcomes-focused solutions. Feel will receive residency at the iPEPS incubator for nine months as well as mentoring and coaching from Janssen, with access to commercial expertise and connections.

George Eleftheriou, CEO and Co-Founder of Feel Therapeutics said: “This exciting development is aligned with our vision to revolutionize the mental health space by providing objective data and emotion recognition technology for the very first time and allow the pharma industry to predict, prevent, and better treat suicide and depression with the appropriate medication.”

The Feel Emotion Sensor is able to translate bio-signals such as EDA, HRV, and ST into emotional state and continuously monitor a person’s mental health state. Feel Therapeutics will use their innovative and proprietary technology to develop and explore various biomarkers related to suicidal thoughts and behaviors, and non-suicidal self-injury in real-life conditions. By analyzing how these biomarkers change among various emotional experiences, both before and after medication, there could be a major breakthrough in helping pharmaceutical companies validate and bring effective depression medication to market faster. Read more

About Feel Therapeutics

Feel Therapeutics, Inc. is developing Digital Biomarkers and Therapeutics to bring objective data and measurement in the way we diagnose, manage, and care for Mental Health. The company is backed by top-tier investors (Felicis, Anthemis, SOSV) and has partnerships with large pharmaceutical companies to develop novel digital biomarkers and bring digital health solutions to market as standalone programs or alongside medications. Feel Therapeutics is headquartered in San Francisco, with additional offices in Europe. For more information, visit or contact us at

You may also like to read